Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

430

Employees430

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

430

Employees430

ARVN Key Statistics

Market cap

556.19M

Market cap556.19M

Price-Earnings ratio

-1.47

Price-Earnings ratio-1.47

Dividend yield

—

Dividend yield—

Average volume

1.95M

Average volume1.95M

High today

—

High today—

Low today

—

Low today—

Open price

$7.40

Open price$7.40

Volume

0.00

Volume0.00

52 Week high

$34.11

52 Week high$34.11

52 Week low

$5.90

52 Week low$5.90

Analyst ratings

55%

of 20 ratings

Buy

55%

Hold

45%

Sell

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.